Nantahala Capital Management LLC purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 600,000 shares of the company's stock, valued at approximately $9,864,000. Nantahala Capital Management LLC owned 1.12% of Upstream Bio as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. US Bancorp DE purchased a new position in Upstream Bio during the fourth quarter worth about $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $28,000. Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio during the 4th quarter valued at approximately $30,000. Tower Research Capital LLC TRC acquired a new position in Upstream Bio in the fourth quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. purchased a new position in Upstream Bio in the fourth quarter worth approximately $142,000.
Upstream Bio Price Performance
Shares of UPB traded down $0.26 during trading on Thursday, reaching $9.00. 267,173 shares of the company traded hands, compared to its average volume of 323,065. The stock has a 50-day simple moving average of $7.92 and a 200-day simple moving average of $14.33. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Recommended Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
